Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05706558 · ClinicalTrials.gov registry record
Retrospective Review of Esophageal Cancer at MSKCC
A clinical trial of Esophageal Cancer and Esophagus Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT05706558 is a study of Esophageal Cancer and Esophagus Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4,000 participants, above the 467-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (757% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05706558, a study of Esophageal Cancer and Esophagus Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.
Conditions Studied
Interventions
- PROCEDURE Esophagectomy
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05706558
The ClinicalTrials.gov registry entry for NCT05706558 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 467-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (757% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Esophagectomy is the first listed.
NCT05706558 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05706558 about?
NCT05706558 is a clinical study titled "Retrospective Review of Esophageal Cancer at MSKCC". Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to ev...
What is the current status of trial NCT05706558?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2016-12-13. Estimated completion is 2027-02.
What conditions does trial NCT05706558 study?
This clinical trial studies the following conditions: Esophageal Cancer, Esophagus Cancer.
What interventions are being tested in trial NCT05706558?
The interventions under investigation include: Esophagectomy (PROCEDURE).
Who is sponsoring clinical trial NCT05706558?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05706558 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.